Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
Ametantrone is the second anthracene derivative to enter clinical trials
and impair triglyceride and/or phospholipid biosynthesis
6-diiodophenoxy]ethyl}diethylamine
1239908-20-3
PubMed PMID: 24900311
Palbociclib 1150 Ametantrone is the second anthracenePalbociclib, also known as PD 0332991, is an orally available cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine threonine kinases that
US$ 36.00
US$ 38.00
US$ 38.00
US$ 38.00
US$ 88.00
US$ 88.00